Literature DB >> 19133811

Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycle.

Mahboobeh Safaeian1, Roni T Falk, Ana Cecilia Rodriguez, Allan Hildesheim, Troy Kemp, Marcus Williams, Lidiana Morera, Manuel Barrantes, Rolando Herrero, Carolina Porras, Ligia Pinto.   

Abstract

OBJECTIVE: The objective of this analysis was to describe patterns and determinants of cervical immunoglobulin A (IgA) and G (IgG) levels during the menstrual cycle.
METHODS: A total of 154 women who attended 3 visits coinciding with the follicular, periovulatory, and luteal phases of their menstrual cycle were studied. Cervical secretions were collected at each visit for determination of total IgA and IgG levels. Questionnaires administered at each visit inquired about demographic characteristics and behavioral practices.
RESULTS: Total IgA and IgG levels were higher among oral contraceptive (OC) users than among naturally cycling women (hereafter, "non-OC users"). IgA and IgG levels decreased at midcycle, particularly among non-OC users. After adjustment for phase of the current cycle, specimen weight, and detection of blood in the sample, report of a recent illness was associated with lower IgA and IgG levels and increased age with higher IgA and IgG levels among OC users and non-OC users. Increased lifetime number of pregnancies was associated with a higher IgA level among non-OC users and a higher IgG level among OC users. Change in immunoglobulin levels between visits was associated with sample weight and the presence of blood for both OC users and non-OC users.
CONCLUSIONS: Phase of the current menstrual cycle and OC use were significant determinants of cervical IgA and IgG levels. The impacts of endogenous and exogenous hormones on cervical immunoglobulin levels should be further investigated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19133811      PMCID: PMC4158917          DOI: 10.1086/596060

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

Authors:  Luisa L Villa; Kevin A Ault; Anna R Giuliano; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Darron R Brown; Alex Ferenczy; Diane M Harper; Laura A Koutsky; Robert J Kurman; Matti Lehtinen; Christian Malm; Sven-Eric Olsson; Brigitte M Ronnett; Finn Egil Skjeldestad; Margareta Steinwall; Mark H Stoler; Cosette M Wheeler; Frank J Taddeo; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Rocio Marchese; Mark T Esser; Janine Bryan; Kathrin U Jansen; Heather L Sings; Gretchen M Tamms; Alfred J Saah; Eliav Barr
Journal:  Vaccine       Date:  2006-05-15       Impact factor: 3.641

Review 2.  Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

Authors:  Margaret Stanley; Douglas R Lowy; Ian Frazer
Journal:  Vaccine       Date:  2006-06-23       Impact factor: 3.641

3.  Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project.

Authors:  R Herrero; M H Schiffman; C Bratti; A Hildesheim; I Balmaceda; M E Sherman; M Greenberg; F Cárdenas; V Gómez; K Helgesen; J Morales; M Hutchinson; L Mango; M Alfaro; N W Potischman; S Wacholder; C Swanson; L A Brinton
Journal:  Rev Panam Salud Publica       Date:  1997-05

4.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

5.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Authors:  Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

6.  Immunoglobulin levels in the serum and cervical mucus of tailed copper IUD users.

Authors:  M K Eissa; R A Sparks; J R Newton
Journal:  Contraception       Date:  1985-07       Impact factor: 3.375

7.  Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures.

Authors:  A Hildesheim; L M McShane; M Schiffman; M C Bratti; A C Rodriguez; R Herrero; L A Morera; F Cardenas; L Saxon; F P Bowman; P A Crowley-Nowick
Journal:  J Immunol Methods       Date:  1999-05-27       Impact factor: 2.303

8.  In situ characterization of leukocytes in the fallopian tube in women with or without an intrauterine contraceptive device.

Authors:  A L Wollen; R Sandvei; S Mørk; J L Marandon; R Matre
Journal:  Acta Obstet Gynecol Scand       Date:  1994-02       Impact factor: 3.636

9.  Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Authors:  Denise Nardelli-Haefliger; Daniel Wirthner; John T Schiller; Douglas R Lowy; Allan Hildesheim; Françoise Ponci; Pierre De Grandi
Journal:  J Natl Cancer Inst       Date:  2003-08-06       Impact factor: 13.506

10.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

View more
  13 in total

1.  Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.

Authors:  Mirte Scherpenisse; Madelief Mollers; Rutger M Schepp; Chris J L M Meijer; Hester E de Melker; Guy A M Berbers; Fiona R M van der Klis
Journal:  Hum Vaccin Immunother       Date:  2012-11-13       Impact factor: 3.452

2.  Interaction of menstrual cycle phase and sexual activity predicts mucosal and systemic humoral immunity in healthy women.

Authors:  Tierney K Lorenz; Gregory E Demas; Julia R Heiman
Journal:  Physiol Behav       Date:  2015-09-21

3.  Determinants of High-Risk Human Papillomavirus Seroprevalence and DNA Prevalence in Mid-Adult Women.

Authors:  Patricia Sadate-Ngatchou; Joseph J Carter; Stephen E Hawes; Qinghua Feng; Taylor Lasof; Joshua E Stern; Tsung-Chieh Jane Fu; Denise A Galloway; Laura A Koutsky; Rachel L Winer
Journal:  Sex Transm Dis       Date:  2016-03       Impact factor: 2.830

Review 4.  Host and Microbiome Interplay Shapes the Vaginal Microenvironment.

Authors:  Myoung Seung Kwon; Heung Kyu Lee
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

5.  Determinants of seropositivity among HPV-16/18 DNA positive young women.

Authors:  Carolina Porras; Christina Bennett; Mahboobeh Safaeian; Sarah Coseo; Ana Cecilia Rodríguez; Paula González; Martha Hutchinson; Silvia Jiménez; Mark E Sherman; Sholom Wacholder; Diane Solomon; Leen-Jan van Doorn; Catherine Bougelet; Wim Quint; Mark Schiffman; Rolando Herrero; Allan Hildesheim
Journal:  BMC Infect Dis       Date:  2010-08-11       Impact factor: 3.090

6.  Determinants and correlation of systemic and cervical concentrations of total IgA and IgG.

Authors:  Mahboobeh Safaeian; Troy Kemp; Roni T Falk; Ana Cecilia Rodriguez; Allan Hildesheim; Marcus Williams; Carolina Porras; Rolando Herrero; Ligia A Pinto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10       Impact factor: 4.254

7.  Determination of cytokine protein levels in oral secretions in patients undergoing radiotherapy for head and neck malignancies.

Authors:  Deborah E Citrin; Ying J Hitchcock; Eun Joo Chung; Jonathan Frandsen; Mary Ellen Urick; William Shield; David Gaffney
Journal:  Radiat Oncol       Date:  2012-04-26       Impact factor: 3.481

8.  Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels.

Authors:  Troy J Kemp; Mahboobeh Safaeian; Samantha Miner; Marcus C Williams; Ana Cecilia Rodriguez; Rolando Herrero; Allan Hildesheim; Ligia A Pinto
Journal:  Front Oncol       Date:  2012-06-25       Impact factor: 6.244

9.  Chlamydia trachomatis Antibody Testing in Vaginal Mucosal Material versus Blood Samples of Women Attending a Fertility Clinic and an STI Clinic.

Authors:  Ingrid V F van den Broek; Jolande A Land; Jan E A M van Bergen; Servaas A Morré; Marianne A B van der Sande
Journal:  Obstet Gynecol Int       Date:  2014-03-13

10.  Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge.

Authors:  Rena D Astronomo; Maria P Lemos; Sandeep R Narpala; Julie Czartoski; Lamar Ballweber Fleming; Kelly E Seaton; Madhu Prabhakaran; Yunda Huang; Yiwen Lu; Katharine Westerberg; Lily Zhang; Mary K Gross; John Hural; Hong-Van Tieu; Lindsey R Baden; Scott Hammer; Ian Frank; Christina Ochsenbauer; Nicole Grunenberg; Julie E Ledgerwood; Kenneth Mayer; Georgia Tomaras; Adrian B McDermott; M Juliana McElrath
Journal:  J Clin Invest       Date:  2021-08-16       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.